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Objectives: In the heterogeneous group of preterm and term neonates, gentamicin and tobramycin are mainly
dosed according to empirical guidelines, after which therapeutic drug monitoring and subsequent dose adapta-
tion are applied. In view of the variety of neonatal guidelines available, the purpose of this study was to evaluate
target concentration attainment of these guidelines, and to propose a new model-based dosing guideline for
these drugs in neonates.
Methods: Demographic characteristics of 1854 neonates (birth weight 390–5200 g, post-natal age 0–27 days)
were extracted from earlier studies and sampled to obtain a test dataset of 5000 virtual patients. Monte
Carlo simulations on the basis of validated models were undertaken to evaluate the attainment of target
peak (5–12 mg/L) and trough (,0.5 mg/L) concentrations, and cumulative AUC, with the existing and proposed
guidelines.
Results: Across the entire neonatal age and weight range, the Dutch National Formulary for Children, the British
National Formulary for Children, Neofax and the Red Book resulted in adequate peak but elevated trough
concentrations (63%–90% above target). The proposed dosing guideline (4.5 mg/kg gentamicin or 5.5 mg/kg
tobramycin) with a dosing interval based on birth weight and post-natal age leads to adequate peak concentra-
tions with only 33%–38% of the trough concentrations above target, and a constant AUC across weight and
post-natal age.
Conclusions: The proposed neonatal dosing guideline for gentamicin and tobramycin results in improved attain-
ment of target concentrations and should be prospectively evaluated in clinical studies to evaluate the efficacy
and safety of this treatment.
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Introduction
In the heterogeneous group of preterm and term neonates, gen-
tamicin and tobramycin are mainly dosed according to empirically
based dosing guidelines (see e.g.1 – 4),after which therapeutic drug
monitoring (TDM) is applied and the dose potentially adapted.
Whereas empirical dosing guidelines improve incrementally, a
model-based dosing guideline can directly indicate the best treat-
ment protocols for reaching target concentrations based on the
available knowledge of the drug, therefore reducing the need for
trial and error. While many dosing guidelines1 – 4 and pharmacoki-
netic models exist for gentamicin and tobramycin, the models
have only rarely been translated to clinical practice.5,6
Recently, a developmental model for the neonatal pharma-
cokinetics of amikacin was constructed and validated with exter-
nal datasets that were not used in model building.7 This model
was subsequently extended to other renally cleared antibiotics
such as netilmicin, vancomycin, tobramycin and gentamicin.8
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This neonatal pharmacokinetic model was derived from data
from 2437 neonates covering a wide range of birth weights
(390–5200 g), which were used as predictors of antenatal mat-
uration, and the whole range of post-natal ages, which were
used as predictors of post-natal maturation.7,8
The goal of this study was to evaluate the performance of
neonatal dosing guidelines for gentamicin and tobramycin of
the Dutch National Formulary for Children (DNFc),1 the British
National Formulary for Children (BNFc),2 Neofax4 and the Red
Book3 in terms of adequate TDM concentrations, and to derive a
model-based neonatal dosing guideline for these aminoglyco-
sides. For this purpose, Monte Carlo simulations were performed
using validated neonatal pharmacokinetic models of gentamicin
and tobramycin to evaluate target peak and trough concentration
attainment, and cumulative AUC over 1 week of treatment.7,8
Methods
Monte Carlo simulations (n¼5000) were conducted for 1 week of treat-
ment according to the dosing protocols outlined in the DNFc,1 the BNFc,2
Neofax4 and the Red Book3 (Tables S1 and S2, available as Supplementary
data at JAC Online). The percentages of peak and trough concentrations
above, at and below target range were computed. Peak concentrations
of 5–12 mg/L1,4 and trough concentrations ,0.5 mg/L2,4 were chosen
as targets for the proposed dosing guideline and the proportion of patients
reaching trough concentrations ,1 mg/L was calculated. As aminoglyco-
side efficacy has been linked to exposure,9 in addition, the cumulative AUC
for 1 week of treatment was calculated according to the proposed dosing
guideline to illustrate the uniformity of exposure across the patients.
For the simulations, a recently developed model for neonatal pharma-
cokinetics of gentamicin, tobramycin, amikacin, netilmicin and vancomy-
cin was used.8 In this model, clearance proved dependent on birth weight,
representing antenatal maturation, on post-natal age, representing post-
natal maturation, and on exposure to ibuprofen (decreasing clearance by
16%). Volume of distribution was dependent on current body weight.8
To be able to perform simulations for the entire preterm and term neo-
natal population, covariate data on birth weight, post-natal age, current
weight and ibuprofen status were extracted from previously published
studies.5 – 7,10 This resulted in a combined dataset of 1854 patients with
an average birth weight of 2100 g (range 390–5200 g, SD 1100 g), an
average current body weight of 2100 g (range 390–5400 g, SD 1100 g)
and an average post-natal age of 1.7 days (range 0 –27 days, SD
2.7 days), with 206 (11%) of the patients receiving ibuprofen for closure
of a persistent ductus arteriosus. From the collected dataset, 5000 indivi-
duals with a post-natal age ,28 days were randomly sampled with
replacement.
Simulations were performed with NONMEM 7.3 using GFortran 4.8.1.11
Data manipulation was performed with R software version 3.1.1.12
Results
Table 1 shows that the existing dosing guidelines resulted in
adequate peak concentrations in most of the cases (75% –
88%), as did the proposed dosing guideline (82% and 91%).
However, the four existing dosing guidelines also resulted in a
high percentage of patients reaching trough concentrations
above target, which is associated with renal and ototoxicity
(Table 1). The proposed new dosing guideline (Table 2) not only
reaches target trough concentrations in 62%–67% of the cases
(Table 1), thereby comparing favourably with, for instance BNFc
with percentages as low as 10%–15% (Figure 1), but also performs
consistently across the observed covariate range of birth weight,
current body weight and post-natal age, as shown in Figure 2.
Approximately 95% of the predicted trough concentrations are
,1 mg/L (Figure 2). Figure S1 shows that, even though the dosing
protocol has been optimized for the attainment of peak and
trough concentrations, it results in uniform 1 week cumulative
AUC values for all subpopulations.
Discussion
In this work, the performance of commonly used gentamicin and
tobramycin dosing guidelines for neonates was evaluated in
terms of target peak and trough concentrations and AUC.
Currently, neonates are dosed according to one of the available
guidelines, after which TDM is performed and subsequent doses
are adapted. As none of the evaluated guidelines performed
well across the heterogeneous group of neonates varying in
weight between 390 and 5200 g, an optimized dosing guideline
was proposed, potentially leading to a reduced need for dose
adaptation after TDM in this special population. It is emphasized
Table 1. Percentage of target peak and trough concentrations of gentamicin/tobramycin above, at and below target concentrations (n¼5000)
Drug Range DNFc1 BNFc2 Red Book3 Neofax4 Proposed
Gentamicin peak .12 6% 18% 13% 20% 9%
peak 5–12 82% 76% 78% 75% 82%
peak ,5 12% 7% 9% 6% 9%
trough ≤1 65% 35% 50% 50% 93%
trough ≤0.5 29% 10% 18% 17% 67%
Tobramycin peak .12 0% 1% 1% 1% 2%
peak 5–12 73% 85% 79% 88% 91%
peak ,5 27% 14% 20% 11% 7%
trough ≤1 74% 46% 63% 61% 90%
trough ≤0.5 37% 15% 26% 24% 62%
Within-target concentrations are in bold.
The percentages do not always add up to 100% because of rounding rules.
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Figure 1. Performance of the proposed dosing guideline versus BNFc guideline during 1 week of treatment summarizing all trough concentrations during
treatment. Grey areas represent concentrations under the target value of 0.5 mg/L.
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Figure 2. Performance of the proposed dosing guideline in terms of target peak and trough concentration attainment for gentamicin (top panels) and
tobramycin (bottom panels) during 1 week of treatment, plotted against covariates birth weight, current body weight and post-natal age (n¼5000). The
broken horizontal lines from top to bottom represent the upper and lower boundaries of target peak concentrations (5–12 mg/L) and the upper limit of
the desired trough concentration (≤0.5 mg/L). The bold horizontal lines represent the median predicted concentrations of peak and trough
concentrations. The grey layers represent the 90th, 70th, 50th and 30th percentiles of the predicted data.
Table 2. Proposed dosing intervals after a uniform dose of gentamicin (4.5 mg/kg) or tobramycin (5.5 mg/kg)
bBW,1 kg (h) bBW between 1 and 2 kg (h) bBW .2 kg (h)
PNA ≤5 days 72 60 48
PNA between 6 and 10 days 60 48 36
PNA between 11 and 20 days 48 36 24
PNA .20 days 36 24 24
bBW, birth body weight; PNA, post-natal age.
The dosing interval should be increased by 12 h if ibuprofen is coadministered for closure of a persistent ductus arteriosus.
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that these dosing guidelines are proposed for neonates without
renal insufficiency.
Even though there is an abundance of both dosing guidelines1 –4
and pharmacokinetic models, the available models have only
rarely been translated to clinical practice.5,6 An important finding
of this study is the need for a different dose for gentamicin versus
tobramycin (4.5 versus 5.5 mg/kg, respectively). This finding can
be explained by the fact that tobramycin clearance and volume
of distribution are higher than the respective pharmacokinetic
parameters for gentamicin in neonates.8 It has also been docu-
mented that gentamicin is more nephrotoxic than tobramy-
cin.13,14 We consider this a further indication that the two drugs
require different doses.
In this work, dosing intervals of up to 72 h are proposed,
whereas the highest dosing interval that we are aware of in an
existing dosing guideline is 60 h.15 There is a general historical
trend in gentamicin and tobramycin dosing, moving from multiple-
daily to once-daily dosing in adults16,17 and towards even less fre-
quent dosing in neonates.5 Given this gradual shift, we propose that
the most premature neonates need yet longer dosing intervals.
Despite the longer dosing interval in the proposed dosing protocol,
the predicted cumulative AUC is not decreased for the most prema-
ture neonates (Figure S1). Further, this cumulative AUC is not based
on merely peak and trough samples; rather, it is based on a vali-
dated two-compartment pharmacokinetic model that is able to
describe the full time course of drug concentrations.7,8
In conclusion, this work provides model-based dosing guidelines
for gentamicin and tobramycin, which reflect state-of-the-art
knowledge about the pharmacokinetics of these drugs and are
also practical, minimizing the risk of dosing errors. Simplicity and
ease of use (i.e. by restricting dosing intervals to multiples of
12 h) were considered a priority when devising the proposed dosing
guideline. Simpler dosing guidelines are associated with fewer dos-
ing errors than more complex ones.18 Prospective validation in clin-
ical studies of these dosing guidelines is needed to evaluate
efficacy and safety of these model-based dosing guidelines.
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